littl
known
platelet
dynam
effect
antiplatelet
therapi
kawasaki
diseas
kd
studi
sought
defin
platelet
activ
dynam
kd
patient
assay
plateletderiv
microparticl
pdmp
measur
plasma
pdmp
level
patient
kd
use
enzymelink
immunosorb
assay
elisa
blood
sampl
collect
day
day
intraven
immunoglobulin
ivig
infus
month
month
onset
kd
measur
pdmp
level
febril
afebril
control
patient
acut
phase
kd
patient
pdmp
level
increas
significantli
ivig
treatment
nmol
ivig
infus
vs
nmol
day
ivig
infus
p
pdmp
level
neg
correl
age
posit
correl
procalcitonin
level
acut
phase
kd
signific
differ
found
pdmp
level
kd
patient
without
coronari
arteri
lesion
cal
elev
pdmp
level
ivig
therapi
significantli
decreas
preivig
level
subacut
phase
nmol
day
ivig
infus
vs
nmol
day
ivig
infus
p
pdmp
level
stay
preivig
level
convalesc
phase
antiplatelet
therapi
given
howev
pdmp
level
rebound
discontinu
aspirin
patient
conclus
enhanc
platelet
activ
note
treatment
kd
peak
immedi
ivig
treatment
recurr
rise
pdmp
level
observ
discontinu
aspirin
although
signific
differ
pdmp
level
month
onset
kd
month
onset
diseas
kawasaki
diseas
kd
acut
febril
system
vasculit
syndrom
unknown
etiolog
occur
primarili
children
younger
year
age
standard
treatment
acut
kd
combin
highdos
gkg
intraven
immunoglobulin
ivig
oral
aspirin
mgkgday
acut
phase
kd
involv
platelet
activ
antiplatelet
therapi
includ
treatment
protocol
phase
find
low
level
antithrombin
iii
deplet
fibrinolyt
system
support
concept
activ
intravascular
clot
format
degrad
occur
patient
notabl
earli
acut
phase
diseas
thrombosi
mainli
occur
arteri
associ
platelet
activ
kd
follow
cessat
fever
day
improv
acut
symptom
dosag
acetylsalicyl
acid
asa
reduc
minimum
level
necessari
inhibit
platelet
aggreg
lowdos
asa
antithrombot
effect
inhibit
thromboxan
aspirin
continu
antithrombot
effect
week
kd
onset
erythrocyt
sediment
rate
esr
thrombocytosi
normal
patient
develop
coronari
arteri
lesion
cal
detect
echocardiographi
howev
decis
total
durat
antiplatelet
therapi
kd
patient
depend
routin
blood
test
includ
level
platelet
microparticl
also
refer
microvesicl
rare
ectosom
submicron
fragment
shed
plasma
membran
stimul
apoptot
cell
plateletderiv
microparticl
pdmp
recent
report
platelet
activ
marker
therefor
pdmp
level
use
index
platelet
activ
pdmp
heterogen
popul
vesicl
gener
plasma
membran
upon
platelet
activ
variou
stimuli
increas
total
number
pdmp
associ
diseas
state
atherosclerosi
diabet
cancer
sepsi
pulmonari
hypertens
howev
littl
known
http
microparticl
link
platelet
dynam
patient
kd
purpos
studi
prove
state
platelet
activ
exist
patient
kd
acut
stage
convalesc
phase
demonstr
use
pdmp
level
evalu
effect
antiplatelet
therapi
kd
enrol
patient
kd
agematch
control
patient
june
august
diagnosi
kd
base
clinic
featur
establish
japanes
kawasaki
diseas
research
committe
complet
kd
defin
least
princip
clinic
sign
japanes
kawasaki
diseas
research
committe
valid
lowdos
asa
mgkgday
continu
week
onset
kd
febril
control
patient
acut
tonsil
conjunct
acut
cervic
lymphaden
afebril
control
patient
acut
gastroenter
acut
urticaria
viral
pneumonia
two
millilit
blood
obtain
put
tube
contain
citrat
anticoagul
sampl
centrifug
g
obtain
plateletpoor
plasma
procedur
perform
room
temperatur
sampl
store
deep
freezer
analysi
pdmp
level
measur
use
enzymelink
immunosorb
assay
elisa
kit
zymuphen
mpactiv
medicago
uppsala
sweden
express
phosphatidylserin
equival
nmol
assay
perform
characterist
follow
detect
threshold
nmol
intraassay
coeffici
variat
cv
interassay
cv
laboratori
data
analyz
ivig
treatment
data
includ
complet
blood
count
esr
level
albumin
aspart
aminotransferas
ast
alanin
aminotransferas
alt
sodium
ntermin
probrain
natriuret
peptid
ntprobnp
creactiv
protein
crp
blood
sampl
collect
patient
kd
follow
time
ivig
infus
day
ivig
infus
day
ivig
infus
month
onset
diseas
month
onset
diseas
control
patient
blood
sampl
pdmp
level
collect
upon
admiss
outpati
clinic
echocardiographi
perform
twice
hospit
immedi
prior
ivig
administr
discharg
twice
followup
observ
upon
termin
lowdos
asa
administr
month
onset
kd
cal
diagnos
base
z
score
left
main
coronari
arteri
proxim
left
anterior
descend
coronari
arteri
proxim
right
coronari
arteri
defin
z
score
valu
z
score
standard
coronari
arteri
dimens
calcul
use
bodi
surfac
area
base
haycock
formula
data
express
mean
standard
deviat
comparison
frequenc
group
analyz
use
test
differ
continu
variabl
among
group
assess
use
ttest
analysi
varianc
anova
signific
differ
calcul
scheff
test
addit
perform
pearson
correl
analysi
identifi
correl
variabl
logist
regress
analysi
use
determin
correl
plasma
pdmp
level
laboratori
valu
includ
ntprobnp
esr
crp
p
valu
less
consid
statist
signific
inform
consent
obtain
parent
children
studi
protocol
approv
eulji
univers
hospit
institut
review
board
irb
inform
consent
confirm
irb
kd
group
compos
boy
girl
whose
mean
age
diagnosi
month
rang
month
total
control
group
enrol
studi
febril
patient
afebril
patient
mean
age
control
group
month
febril
patient
month
afebril
patient
febril
control
group
epsteinbarr
viru
infect
confirm
patient
adenoviru
identifi
patient
use
nasopharyng
swab
afebril
group
parainfluenza
viru
bocaviru
coronaviru
identifi
patient
use
nasopharyng
swab
patient
kd
patient
diagnos
complet
kd
patient
incomplet
kd
mean
time
start
ivig
treatment
fever
day
five
patient
respond
initi
ivig
infus
patient
respond
second
ivig
treatment
without
corticosteroid
treatment
three
patient
cross
methylprednisolon
puls
therapi
second
ivig
treatment
mean
period
lowdos
asa
usag
patient
kd
day
rang
day
total
patient
experienc
recurr
kd
followup
period
upon
admiss
level
white
blood
cell
wbc
neutrophil
esr
crp
ntprobnp
significantli
higher
kd
patient
control
patient
tabl
level
hemoglobin
lower
kd
patient
compar
afebril
control
patient
p
measur
level
pdmp
plasma
febril
control
afebril
control
subject
mean
plasma
pdmp
level
control
group
significantli
differ
nmol
febril
control
vs
nmol
afebril
control
p
fig
patient
kd
mean
pdmp
level
ivig
treatment
nmol
plasma
pdmp
level
day
ivig
infus
nmol
significantli
higher
febril
control
patient
p
kd
patient
cal
show
significantli
elev
neutrophil
esr
level
compar
kd
patient
without
cal
differ
pdmp
level
patient
refractori
kd
patient
respond
initi
ivig
treatment
differ
found
pdmp
albumin
ntprobnp
crp
level
kd
patient
without
cal
tabl
fig
show
chang
pdmp
level
acut
subacut
day
ivig
infus
convalesc
phase
ivig
therapi
plasma
pdmp
level
significantli
creas
nmol
ivig
infus
vs
nmol
day
ivig
infus
p
pdmp
level
day
ivig
infus
nmol
significantli
lower
preivig
level
p
addit
pdmp
level
month
onset
kd
nmol
significantli
lower
preivig
level
p
howev
patient
recurr
rise
pdmp
level
day
rang
day
asa
discontinu
mean
pdmp
level
month
onset
kd
nmol
higher
pdmp
level
month
onset
kd
although
reach
statist
signific
p
tabl
show
comparison
patient
show
rebound
pdmp
level
pdmp
level
patient
recurr
rise
significantli
higher
patient
show
rebound
pdmp
level
month
onset
kd
p
ten
kd
patient
show
mild
dilat
coronari
arteri
acut
stage
kd
patient
cal
upon
admiss
exhibit
normal
coronari
arteri
one
month
discharg
none
kd
patient
develop
coronari
arteri
aneurysm
confirm
serial
echocardiographi
ivig
therapi
differ
kd
patient
febril
control
patient
degre
left
ventricular
fraction
shorten
ratio
mitral
peak
veloc
earli
fill
period
earli
diastol
mitral
annular
veloc
measur
tissu
doppler
imag
tdi
increas
acut
stage
kd
patient
compar
febril
control
patient
although
differ
statist
signific
tabl
patient
kd
age
neg
correl
initi
pdmp
level
r
p
tabl
addit
posi
pdmp
plateletderiv
microparticl
kd
kawasaki
diseas
bmi
bodi
mass
index
wbc
white
blood
cell
crp
creactiv
protein
hdlc
highdens
lipoproteincholesterol
ntprobnp
ntermin
probrain
natriuret
peptid
tive
correl
found
pdmp
procalcitonin
level
ivig
treatment
acut
stage
kd
r
p
febril
control
pdmp
level
significantli
correl
elev
hdl
level
r
p
pdmp
level
patient
kd
rebound
month
discontinu
asa
multivari
logist
regress
analysi
serum
ntprobnp
crp
level
risk
factor
rebound
pdmp
level
correl
clinic
variabl
rebound
pdmp
level
discontinu
asa
tabl
studi
conduct
determin
role
pdmp
biomark
antiplatelet
agent
kd
investig
serial
chang
plasma
pdmp
level
per
stage
kd
studi
show
pdmp
level
significantli
elev
patient
kd
immedi
ivig
treatment
level
pdmp
decreas
subacut
stage
convalesc
phase
antiplatelet
therapi
platelet
wellestablish
compon
hemostat
system
recogn
role
innat
immun
recent
sever
addit
function
platelet
demonstr
pathogenesi
variou
diseas
inflamm
import
clinic
sign
activ
blood
platelet
typic
find
patient
system
inflamm
sepsi
inflammatori
condit
platelet
also
show
robust
interact
leukocyt
activ
platelet
adher
damag
vessel
wall
promot
local
recruit
leukocyt
thrombocytosi
univers
find
patient
subacut
stage
kd
specif
kd
previou
epidemiolog
studi
platelet
count
found
elev
patient
chronic
inflammatori
diseas
malign
myeloprolif
disord
degre
platelet
activ
close
associ
presenc
coronari
arteri
complic
acut
stage
kd
subacut
stage
kd
platelet
count
increas
rapidli
sever
stenosi
obstruct
report
occur
due
thrombi
main
coronari
arteri
aneurysm
present
studi
degre
thrombocytosi
significantli
differ
group
kd
without
cal
pdmp
endoplasm
reticulumderiv
vesicl
rang
size
discharg
platelet
upon
activ
sort
stimulu
pdmp
abund
microparticl
blood
stream
constitut
approxim
circul
microparticl
detect
peripher
blood
normal
individu
microparticl
elev
clinic
situat
thrombot
risk
increas
signific
differ
pdmp
level
observ
kd
patient
without
cal
present
studi
recent
research
focus
microparticl
patholog
condit
vesicl
easili
mistaken
pure
detriment
howev
microparticl
benefici
present
healthi
individu
present
studi
show
pdmp
level
control
group
significantli
differ
preivig
kd
group
probabl
control
group
studi
healthi
control
diseas
control
pathophysiolog
condit
pdmp
appear
deriv
mostli
procoagul
circul
speci
leukocyt
endotheli
origin
less
repres
inflamm
coagul
link
process
mani
diseas
septicemia
pdmp
known
amplifi
respons
activ
endothelium
pdmp
initi
inflamm
barri
cowork
demonstr
pdmp
deliv
arachidon
acid
endotheli
cell
result
upregul
intercellular
adhes
subsequ
adhes
monocyt
therefor
microparticl
consequ
diseas
also
casual
role
pathogenesi
inflammatori
diseas
although
pdmp
recent
receiv
great
deal
attent
marker
platelet
activ
adult
littl
data
pdmp
level
pediatr
patient
taki
et
al
report
enhanc
platelet
aggreg
note
high
frequenc
treatment
kd
use
particl
count
method
suggest
platelet
activ
continu
second
stage
ie
start
ivig
therapi
day
platelet
activ
inhibit
antiplatelet
agent
recent
studi
demonstr
ivig
treatment
significantli
decreas
pdmp
level
patient
acut
kd
show
pdmp
level
immedi
day
ivig
treatment
significantli
lower
preivig
level
contrast
could
find
signific
increas
pdmp
level
day
ivig
treatment
compar
preivig
level
specul
differ
probabl
due
differ
across
elisa
kit
use
studi
time
chang
asa
dosag
abovement
report
immedi
chang
dose
asa
antiinflammatori
dose
mgkgday
antithrombot
dose
mg
kgday
patient
becam
afebril
howev
maintain
high
dose
asa
mgkgday
patient
afebril
day
acut
symptom
improv
elisa
test
depend
qualiti
reagent
usual
antibodi
addit
possibl
interfer
solubl
antigen
may
result
underestim
microparticl
level
antigen
captur
present
studi
use
zymuphen
mpactiv
medicago
elisa
measur
prothrombinas
activ
elisa
http
reader
biorad
hercul
ca
usa
measur
sampl
wavelength
nm
dilut
assay
plasma
sampl
supplement
calcium
factor
xa
thrombin
inhibitor
introduc
micropl
well
coat
streptavidin
biotinyl
annexin
v
incub
phospholipid
concentr
limit
factor
elisa
test
even
flow
cytometri
consid
gold
standard
microparticl
detect
still
technic
limit
concern
detect
small
microparticl
nm
nm
therefor
microparticl
activ
analyz
prothrombinas
assay
elisa
easili
perform
show
signific
correl
result
present
studi
pdmp
level
patient
rebound
aspirin
discontinu
even
though
cal
result
suggest
vascular
inflamm
may
persist
convalesc
phase
even
morpholog
coronari
arteri
appear
normal
onechocardiographi
caus
clinic
implic
persist
platelet
activ
acut
stage
patient
kd
probabl
due
persist
subclin
lowgrad
inflamm
kd
recent
studi
report
children
previou
episod
kd
show
increas
platelet
activ
compar
healthi
particip
despit
appar
vascular
abnorm
followup
asa
first
antiplatelet
agent
use
primari
secondari
prevent
cardiovascular
event
irrevers
bind
asa
inhibit
thu
block
platelet
aggreg
induc
vasoconstrict
kd
patient
lowdos
asa
continu
antithrombot
effect
week
kd
onset
moreov
recent
evid
support
fact
antiplatelet
therapi
affect
host
immun
sever
studi
shown
asa
clopidogrel
diminish
risk
atherothrombot
event
also
reduc
marker
system
inflamm
includ
crp
proinflammatori
cytokin
antiplatelet
medic
clopidogrel
ticagrelor
also
associ
reduc
mortal
patient
sepsi
without
caus
excess
bleed
patient
cardiovascular
diseas
inhibit
shed
microparticl
account
efficaci
variou
drug
abciximab
platelet
glycoprotein
iibiiia
antagonist
act
potent
antiplatelet
agent
kd
patient
giant
coronari
arteri
aneurysm
thrombosi
recent
studi
show
abciximab
treatment
import
role
manag
sever
complic
kd
although
prospect
random
control
studi
need
fulli
evalu
efficaci
prevent
thrombot
complic
promot
vascular
remodel
current
studi
limit
first
enrol
rel
small
number
patient
therefor
could
determin
whether
result
also
applic
differ
geograph
popul
second
coronari
aneurysm
sequela
kd
group
lastli
could
perform
platelet
function
test
adenosin
diphosph
adp
induc
platelet
aggreg
test
patient
kd
could
check
followup
pdmp
level
control
patient
would
requir
larg
amount
addit
blood
drawn
small
infant
young
children
conclus
enhanc
platelet
activ
note
treatment
kd
convalesc
phase
kd
long
month
onset
kd
result
indic
time
asa
discontinu
evalu
individu
patient
kd
monitor
biomark
platelet
activ
import
use
sentinel
patient
high
risk
thrombosi
intracardiac
stent
complex
congenit
heart
diseas
kd
studi
larger
sampl
size
longer
followup
period
requir
clarifi
clinic
signific
pdmp
pathogenesi
treatment
kd
